The Technical Analyst
Select Language :
Orchard Therapeutics PLC [ORTX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Orchard Therapeutics PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals

Orchard Therapeutics PLC is listed at the  Exchange

0.30% $16.70

America/New_York / 23 jan 2024 @ 16:00


Orchard Therapeutics PLC: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 380.11 mill
EPS: -4.10
P/E: -4.07
Earnings Date: Mar 05, 2024
SharesOutstanding: 22.76 mill
Avg Daily Volume: 0.105 mill
RATING 2024-01-23
B
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Strong Buy
P/E: Sell
Price To Book: Buy
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -4.07 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.69x
Company: PE -4.07 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 16.64 - 16.76

( +/- 0.35%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-01-24 Secor Alicia Sell 46 000 Stock Option (Right to Buy)
2024-01-24 Secor Alicia Sell 105 000 Stock Option (Right to Buy)
2024-01-24 Geraghty James A Sell 44 391 Ordinary Shares
2024-01-24 Geraghty James A Sell 46 000 Stock Option (Right to Buy)
2024-01-24 Geraghty James A Sell 105 000 Stock Option (Right to Buy)
INSIDER POWER
-27.29
Last 99 transactions
Buy: 13 341 271 | Sell: 6 351 136

Forecast: 01:40 - $18.92

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $16.70 (0.30% )
Volume 0.372 mill
Avg. Vol. 0.105 mill
% of Avg. Vol 353.86 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Orchard Therapeutics PLC

Last 12 Months

Last 12 months chart data with high, low, open and close for Orchard Therapeutics PLC

RSI

Intraday RSI14 chart for Orchard Therapeutics PLC

Last 10 Buy & Sell Signals For ORTX

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Orchard Therapeutics PLC

ORTX

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Last 10 Buy Signals

Date Signal @
RMBSMar 28 - 14:04$62.23
INVUSDMar 28 - 14:0257.54
DUOLMar 28 - 14:02$219.65
WDAYMar 28 - 14:01$274.51
NVDLMar 28 - 14:0241.50
NVDAMar 28 - 14:02$902.58
JEPQMar 28 - 14:0154.21
^SP500-25Mar 28 - 14:011 485.14
ABNBMar 28 - 14:01$165.61
TSLAMar 28 - 14:01$176.67

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.